An Interview With Cybin CEO Doug Drysdale

From positive results for their new lead compound, to partnerships with big names like Deepak Chopra, to the announcement of a successful patent for their CYB-004

 DMT molecule — Cybin has been one of the industry’s most consistent headline-makers over the past several months.

We sat down with CEO Doug Drysdale to discuss these and other industry topics, including Cybin’s developmental pipeline, upcoming clinical trials, and the state of the psychedelic medicine market (and when my shroom stock might finally pull of out the gutter!)